Last updated: April 26, 2026
Pemetrexed disodium is primarily supplied through two channels: (1) generic and branded API and finished-dose sourcing for global commercial distribution and (2) contract manufacturing and packaging for label owners and distributors. The supply base for pemetrexed disodium concentrates around a limited set of large oncology-API and sterile-injectable CMOs/FDAspace operators, with additional participation from regional generic players.
Which companies supply pemetrexed disodium (API and/or finished product)?
API and intermediates supply signals (typical sourcing model)
Pemetrexed disodium is manufactured and supplied in one of three ways:
- Direct API manufacture by an oncology-focused chemical API producer
- API procurement via distributor networks (API brokers plus regional chemical distributors)
- Finished-dose CMOs that source API and perform aseptic fill-finish or final sterile packaging under contract
The most visible public footprint in global supply is from companies that both commercialize oncology injectables and maintain active generic manufacturing programs in sterile sterile settings.
Finished-dose market suppliers (brands and generics)
In practice, label holders for pemetrexed-based oncology products distribute through a network of:
- Global pharmaceutical distributors (tender and hospital procurement)
- Regional wholesalers (tender-aligned supply into oncology centers)
- Group purchasing organization (GPO) aligned fulfillment in the US and EU
Because “pemetrexed disodium” is also commonly referenced as the active in finished pemetrexed oncology injectables (often described by strength and packaging), supply identification is typically anchored to the marketed product and its authorized manufacturer, not only to “API pemetrexed disodium” listings.
Who are the dominant upstream manufacturers and CMOs that typically participate in pemetrexed supply?
Common manufacturer categories in pemetrexed supply chains
Supplier selection for pemetrexed disodium is usually filtered by:
- Capability for controlled substance equivalents is not required; the key constraint is sterile injectable quality systems and aseptic processing
- Regulatory history for oncology sterile injectables (high scrutiny for sterility assurance, container closure integrity, and validated hold times)
- Availability of commercial-scale synthetic routes and impurity controls
In procurement terms, buyer due diligence concentrates on:
- GMP status and inspection history
- DMF/MAH/CEP linkage (where applicable)
- Sterile manufacturing approvals and batch traceability
- Supply continuity commitments and allocation policies during shortage periods
What procurement-ready supplier structure should you expect for pemetrexed disodium?
1) API sourcing routes
Most buyers procure through either:
- Direct API purchase agreements with an API manufacturer
- Approved distributor channels that hold inventory buffers and ship to sterile-fill finish sites
Procurement proof points typically requested
- CoA and spec sheet for pemetrexed disodium (identity, assay, related substances, residual solvents, sulfate/salt specs)
- Batch certificates with manufacturing site identifiers
- Analytical methods alignment (HPLC/LC-MS identity and impurity panels)
2) Finished-dose sourcing routes
For hospital and distributor channels, buyers typically receive:
- Sterile vial product (typically single-dose) supplied under GMP aseptic fill-finish standards
- Packaging and labeling compliant with regional requirements
Procurement proof points typically requested
- GMP batch records traceability
- Sterility assurance controls and container closure integrity documentation
- Stability data for marketed strength and storage conditions
What “supplier list” can be provided from public, citable sources?
No citable supplier list can be produced from the information available in this request. A complete and accurate answer requires product- and territory-specific authorizations or manufacturer identifiers tied to pemetrexed disodium API and/or finished injectable strength, and those are not provided here.
Supply risk: what constraints control availability?
Even without a named roster, the procurement risk profile for pemetrexed disodium typically tracks these drivers:
- Sterile injectable capacity bottlenecks (aseptic fill-finish slots are capacity constrained)
- API purity and impurity spec tightening (a downstream change triggers batch rejection risk)
- Inspection outcomes at key sites (fewer suppliers means faster allocation ripple effects)
- Allocation during oncology supply disruptions (priority rules for major tenders)
Operational guidance for buyers (supplier qualification criteria)
A pemetrexed disodium supplier evaluation is typically structured around:
- GMP compliance and inspection record at the manufacturing site
- DMF/CEP status and ability to support regulatory filings
- Batch-to-batch consistency controls (related substances profile and assay drift thresholds)
- Cold chain and handling requirements for finished sterile injectables where applicable
- Commercial reliability: lead times, forecast acceptance, and allocation terms
Key Takeaways
- Pemetrexed disodium supply is dominated by a narrow set of oncology-capable API manufacturers and sterile injectable CMOs that support aseptic fill-finish.
- Supplier identification for “pemetrexed disodium” is usually best anchored to the authorized marketed pemetrexed injectable (strength and packaging) rather than only to an API name.
- Buyer qualification centers on GMP track record, impurity/assay controls, regulatory documentation linkage, and sterile injectable capacity assurance.
FAQs
1) Are suppliers of pemetrexed disodium usually the same as suppliers of pemetrexed finished injectable?
Not usually. Many suppliers provide either API upstream or finished-dose sterile product downstream. Some vertically integrate, but procurement often separates API and sterile fill-finish.
2) What criteria matter most when selecting a pemetrexed disodium supplier?
GMP compliance for the relevant site, ability to meet impurity-related substances specs, documentation readiness for regulatory filings, and continuity of sterile injectable capacity.
3) Why do shortages happen for pemetrexed-based oncology injectables?
Capacity constraints in sterile fill-finish, tight impurity acceptance windows, and reduced availability of eligible API supply can trigger allocation.
4) How do buyers typically verify API quality for pemetrexed disodium?
By reviewing CoA/specification sheets, analytical method alignment, batch traceability, and related substances panels across consecutive production lots.
5) Where is the most actionable supplier information usually found?
In authorized product listings tied to specific strengths and vial configurations, where manufacturers and sites are documented for the marketed injectable.
References
[1] No citable sources were provided or identifiable from the request content.
